Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 45

1.

A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.

Stockburger C, Miano D, Baeumlisberger M, Pallas T, Arrey TN, Karas M, Friedland K, Müller WE.

J Alzheimers Dis. 2016;50(1):201-15. doi: 10.3233/JAD-150687.

PMID:
26639968
2.

Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines.

Bandala C, Cortés-Algara AL, Mejía-Barradas CM, Ilizaliturri-Flores I, Dominguez-Rubio R, Bazán-Méndez CI, Floriano-Sánchez E, Luna-Arias JP, Anaya-Ruiz M, Lara-Padilla E.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8411-8. eCollection 2015.

3.

Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis.

Lee J, Daniels V, Sands ZA, Lebon F, Shi J, Biggin PC.

PLoS One. 2015 Feb 18;10(2):e0116589. doi: 10.1371/journal.pone.0116589. eCollection 2015.

4.

The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae.

Madeo M, Kovács AD, Pearce DA.

J Biol Chem. 2014 Nov 28;289(48):33066-71. doi: 10.1074/jbc.C114.584516. Epub 2014 Oct 17.

5.

Synaptic vesicle protein 2 (SV2) isoforms.

Bandala C, Miliar-García A, Mejía-Barradas CM, Anaya-Ruiz M, Luna-Arias JP, Bazán-Méndez CI, Gómez-López M, Juárez-Méndez S, Lara-Padilla E.

Asian Pac J Cancer Prev. 2012;13(10):5063-7.

6.

Genetic variation at the synaptic vesicle gene SV2A is associated with schizophrenia.

Mattheisen M, Mühleisen TW, Strohmaier J, Treutlein J, Nenadic I, Alblas M, Meier S, Degenhardt F, Herms S, Hoffmann P, Witt SH, Giegling I, Sauer H, Schulze TG, Rujescu D, Nöthen MM, Rietschel M, Cichon S.

Schizophr Res. 2012 Nov;141(2-3):262-5. doi: 10.1016/j.schres.2012.08.027. Epub 2012 Sep 24.

PMID:
23017826
7.

Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.

Shi J, Anderson D, Lynch BA, Castaigne JG, Foerch P, Lebon F.

Biochem Soc Trans. 2011 Oct;39(5):1341-7. doi: 10.1042/BST0391341.

PMID:
21936812
8.

Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.

de Groot M, Aronica E, Heimans JJ, Reijneveld JC.

Neurology. 2011 Aug 9;77(6):532-9. doi: 10.1212/WNL.0b013e318228c110. Epub 2011 Jul 27.

PMID:
21795655
9.

Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.

de Groot M, Toering ST, Boer K, Spliet WG, Heimans JJ, Aronica E, Reijneveld JC.

Neuro Oncol. 2010 Mar;12(3):265-73. doi: 10.1093/neuonc/nop028. Epub 2010 Jan 6.

10.

Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo.

Karsenty G, Rocha J, Chevalier S, Scarlata E, Andrieu C, Zouanat FZ, Rocchi P, Giusiano S, Elzayat EA, Corcos J.

Prostate. 2009 Aug 1;69(11):1143-50. doi: 10.1002/pros.20958.

PMID:
19399787
11.

Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers.

Toering ST, Boer K, de Groot M, Troost D, Heimans JJ, Spliet WG, van Rijen PC, Jansen FE, Gorter JA, Reijneveld JC, Aronica E.

Epilepsia. 2009 Jun;50(6):1409-18. doi: 10.1111/j.1528-1167.2008.01955.x. Epub 2009 Feb 12.

12.

Amyloid beta a4 precursor protein-binding family B member 1 (FE65) interactomics revealed synaptic vesicle glycoprotein 2A (SV2A) and sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) as new binding proteins in the human brain.

Nensa FM, Neumann MH, Schrötter A, Przyborski A, Mastalski T, Susdalzew S, Looβe C, Helling S, El Magraoui F, Erdmann R, Meyer HE, Uszkoreit J, Eisenacher M, Suh J, Guénette SY, Röhner N, Kögel D, Theiss C, Marcus K, Müller T.

Mol Cell Proteomics. 2014 Feb;13(2):475-88. doi: 10.1074/mcp.M113.029280. Epub 2013 Nov 27.

13.

Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.

Daniels V, Wood M, Leclercq K, Kaminski RM, Gillard M.

Br J Pharmacol. 2013 Jul;169(5):1091-101. doi: 10.1111/bph.12192.

14.

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.

Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B.

Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6. Epub 2004 Jun 21.

15.

The synaptic vesicle protein SV2 is complexed with an alpha5-containing laminin on the nerve terminal surface.

Son YJ, Scranton TW, Sunderland WJ, Baek SJ, Miner JH, Sanes JR, Carlson SS.

J Biol Chem. 2000 Jan 7;275(1):451-60.

16.

SV2, a brain synaptic vesicle protein homologous to bacterial transporters.

Bajjalieh SM, Peterson K, Shinghal R, Scheller RH.

Science. 1992 Aug 28;257(5074):1271-3.

PMID:
1519064
17.
18.

Expression pattern of synaptic vesicle protein 2 (SV2) isoforms in patients with temporal lobe epilepsy and hippocampal sclerosis.

Crèvecoeur J, Kaminski RM, Rogister B, Foerch P, Vandenplas C, Neveux M, Mazzuferi M, Kroonen J, Poulet C, Martin D, Sadzot B, Rikir E, Klitgaard H, Moonen G, Deprez M.

Neuropathol Appl Neurobiol. 2014 Feb;40(2):191-204. doi: 10.1111/nan.12054.

PMID:
23617838
19.

No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.

Lynch JM, Tate SK, Kinirons P, Weale ME, Cavalleri GL, Depondt C, Murphy K, O'Rourke D, Doherty CP, Shianna KV, Wood NW, Sander JW, Delanty N, Goldstein DB, Sisodiya SM.

Epilepsy Res. 2009 Jan;83(1):44-51. doi: 10.1016/j.eplepsyres.2008.09.003. Epub 2008 Oct 31.

PMID:
18977120
20.

Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A).

Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM.

Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15268-73.

Supplemental Content

Support Center